- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03847558
Sexual Maturation in β-Thalassemia Major Patients in Assiut University Hospital
Assessment of Sexual Maturation in β-Thalassemia Major Patients Receiving Iron Chelation Therapy in Assiut University Hospital
Study Overview
Status
Detailed Description
Thalassemia refers to a group of inherited diseases characterized by decreased or absent synthesis of normal globin chains . The direct consequence is an imbalance of the alpha and beta globin chain synthesis that results in anemia from ineffective erythropoiesis and hemolysis.
The term thalassemia major refers to the severe form that is often associated with life-long transfusion dependent anemia.
Hypogonadism is the most frequently reported endocrine complication, affecting 70-80% of thalassemia major patients. Hypogonadism is likely to be caused by iron deposits in the gonads, pituitary gland or both.
Hypogonadotropic hypogonadism resulting from iron deposition in the pituitary gonadotrope is more commonly found than gonadal iron deposition in ovaries or testes occurs.
Iron deposition in the anterior pituitary gland can be demonstrated beginning in the first decade of life, but clinical manifestations are usually not evident until the onset of puberty. At the earlier stage, only a diminished gonadotropin reserve with intact gonadotropin pulse was observed .
The direct effect of iron, in particular that of NTBI(non-transferrin-bound iron) on the ovaries and testes is currently unknown. The ovarian reserve is preserved in the majority of female thalassemia patients, even in women with amenorrhea. In males, histological examination of testicular tissues from autopsies demonstrated testicular interstitial fibrosis with small, heavily pigmented, undifferentiated seminiferous tubules and an absence of Leydig cells .
There are three main clinical presentations of the HPG(hypothalamic pituitary gonadal axis)axis derangement in thalassemia major, including delayed puberty, arrested puberty and hypogonadism. Delayed puberty is defined as the absence of any pubertal signs by 14 years in boys and 13 years in girls . Arrested puberty is defined as the absence of further pubertal progression for more than 1 year after puberty has started.
Chelation therapy with desferoxamine before the age of puberty has helped patients to attain normal sexual maturation in some studies but not in others. In a study of 40 patients with transfusion-dependent thalassemia major, 90% of 19 patients who began treatment with desferoxamine before the age of 10 had normal sexual development compared with only 38% of those treated after the age of 10. In contrast, another study reported no difference in the frequency of pubertal maturation when iron chelation therapy was started at the age of 10 or earlier. Serum ferritin levels were still higher than normal in previous studies.
After a period of 5-7 years, 50% of hypogonadal males achieved normal testosterone levels and 32% of amenorrheic women became pregnant, either spontaneously or using in vitro fertilization . With modern medications, iron-induced hypogonadism may be reversible with intensive iron chelation regimens.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- β-thalassemic Patients aged 10 years and older
- β-thalassemic patients receiving regular blood transfusions
- All patients are on chelation therapy
Exclusion Criteria:
- β-thalassemic patients with major system complications as cardiac ,renal or hepatic.
- Patients not receiving chelation therapy
- Patients with other hemolytic anemia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
sexual maturation in patient receiving iron chelation
assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
|
assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sexual maturation in patients receiving regular chelation will be compared to patients not receiving chelation helps us to improve quality of life for these patients and have normal sexual life
Time Frame: 1 year
|
The present study will be carried out on previously diagnosed transfusion dependent thalassemia patients under chelation therapy in Assiut University children hospital.
|
1 year
|
calculate body mass index (kg/m^2)
Time Frame: 1 year
|
assesment of hieght in meters,weight in kilograms.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Assiut Univ Children Hospitals
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on β-Thalassemia Major Patients Receiving Chelation Therapy
-
University of Illinois at ChicagoTerminatedPatients Receiving Physical TherapyUnited States
-
BGI-researchShenzhen Children's HospitalNot yet recruiting
-
Bioray LaboratoriesXiangya Hospital of Central South University; The 923rd Hospital of Joint Logistics...Completedβ Thalassemia MajorChina
-
Bioray LaboratoriesPLA 923 HospitalTerminated
-
bluebird bioCompletedβ-thalassemia MajorUnited States, Australia, Thailand
-
Novartis PharmaceuticalsWithdrawn
-
Aghia Sophia Children's Hospital of AthensUnknownAsplenia | β-thalassemia MajorGreece
-
Ain Shams UniversityUnknownBeta-thalassemia | Serum Ferritin | Iron Chelation TherapyEgypt
-
Novartis PharmaceuticalsTerminatedCardiac Iron Overload | Transfusion-dependent β-thalassemia PatientsGreece
-
Ain Shams UniversityUnknownThalassemia Major | Iron Chelation | Vitamin cEgypt
Clinical Trials on FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males
-
Instituto BernabeuUnknownReproductive Techniques, AssistedSpain
-
Vietnam National UniversityCompleted
-
IBSA Institut Biochimique SACompletedOocyte DonationSpain
-
NRG OncologyNational Cancer Institute (NCI)SuspendedProstate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8Canada, United States
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompletedOvarian StimulationSpain
-
National Foundation for Fertility ResearchFertility Laboratories Of ColoradoUnknownInfertility | Reproductive Techniques, AssistedUnited States
-
IRCCS Azienda Ospedaliera Universitaria San Martino...CompletedEndometriosis | Surgery | EndometriomaItaly
-
National and Kapodistrian University of AthensCompleted
-
Eunice Kennedy Shriver National Institute of Child...TerminatedKallmann Syndrome | HypogonadismUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Karolinska University Hospital; Hvidovre University... and other collaboratorsCompleted